메뉴 건너뛰기




Volumn 12, Issue 6, 2010, Pages 654-661

Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet

Author keywords

Drug transporting enzyme; EGFR; epidermal growth factor receptor; pharmacogenetics; polymorphism; TKI; tyrosine kinase inhibitor

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DASATINIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GUANINE; IMATINIB; LAPATINIB; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; SORAFENIB; SUNITINIB; THYMINE;

EID: 79952938785     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (9)

References (46)
  • 1
    • 70449704111 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of tyrosine kinase inhibitors
    • van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev (2009) 35(8):692-706.
    • (2009) Cancer Treat Rev , vol.35 , Issue.8 , pp. 692-706
    • Van Erp, N.P.1    Gelderblom, H.2    Guchelaar, H.J.3
  • 3
    • 22044442973 scopus 로고    scopus 로고
    • Tyrosine kinases as targets for cancer therapy
    • DOI 10.1056/NEJMra044389
    • Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med (2005) 353(2):172-187. (Pubitemid 41058349) (Pubitemid 41058349)
    • (2005) New England Journal of Medicine , vol.353 , Issue.2 , pp. 172-187
    • Krause, D.S.1    Van Etten, R.A.2
  • 4
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • DOI 10.1126/science.1062538
    • Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplifcation. Science (2001) 293(5531):876-880. (Pubitemid 32743979) (Pubitemid 32743979)
    • (2001) Science , vol.293 , Issue.5531 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3    Hsu, N.4    Paquette, R.5    Nagesh Rao, P.6    Sawyers, C.L.7
  • 5
    • 0001686739 scopus 로고    scopus 로고
    • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    • DOI 10.1016/S1535-6108(02)00096-X
    • Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL: Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2(2):117-125. (Pubitemid 41039112) (Pubitemid 41039112)
    • (2002) Cancer Cell , vol.2 , Issue.2 , pp. 117-125
    • Shah, N.P.1    Nicoll, J.M.2    Nagar, B.3    Gorre, M.E.4    Paquette, R.L.5    Kuriyan, J.6    Sawyers, C.L.7
  • 8
    • 66849106721 scopus 로고    scopus 로고
    • Using germline genotype in cancer pharmacogenetic studies
    • McWhinney SR, McLeod HL: Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics (2009) 10(3): 489-493.
    • (2009) Pharmacogenomics , vol.10 , Issue.3 , pp. 489-493
    • McWhinney, S.R.1    McLeod, H.L.2
  • 11
    • 4544290436 scopus 로고    scopus 로고
    • Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms
    • DOI 10.1016/j.leukres.2004.03.007, PII S014521260400092X
    • Bruck P, Wassmann B, Lopez ER, Hoelzer D, Ottmann OG: Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms. Leuk Res (2004) 28(11): 1153-1157. (Pubitemid 39243238) (Pubitemid 39243238)
    • (2004) Leukemia Research , vol.28 , Issue.11 , pp. 1153-1157
    • Bruck, P.1    Wassmann, B.2    Lopez, E.R.3    Hoelzer, D.4    Ottmann, O.G.5
  • 12
    • 77953968068 scopus 로고    scopus 로고
    • Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
    • Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, Lipton JH: Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol (2010) 21(6):1179-1188.
    • (2010) Ann Oncol , vol.21 , Issue.6 , pp. 1179-1188
    • Kim, D.H.1    Xu, W.2    Kamel-Reid, S.3    Liu, X.4    Jung, C.W.5    Kim, S.6    Lipton, J.H.7
  • 13
    • 1842426649 scopus 로고    scopus 로고
    • Correlation of Major Cytogenetic Response with a Pharmacogenetic Marker in Chronic Myeloid Leukemia Patients Treated with Imatinib (STI571)
    • DOI 10.1158/1078-0432.CCR-0785-3
    • Dressman MA, Malinowski R, McLean LA, Gathmann I, Capdeville R, Hensley M, Polymeropoulos MH, International Randomized Study of Interferon-α versus ST1571 Study Group: Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). Clin Cancer Res (2004) 10(7):2265-2271. (Pubitemid 38445683) (Pubitemid 38445683)
    • (2004) Clinical Cancer Research , vol.10 , Issue.7 , pp. 2265-2271
    • Dressman, M.A.1    Malinowski, R.2    McLean, L.A.3    Gathmann, I.4    Capdeville, R.5    Hensley, M.6    Polymeropoulos, M.H.7
  • 17
    • 68049087941 scopus 로고    scopus 로고
    • Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia
    • Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH: Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res (2009) 15(14):4750-4758.
    • (2009) Clin Cancer Res , vol.15 , Issue.14 , pp. 4750-4758
    • Kim, D.H.1    Sriharsha, L.2    Xu, W.3    Kamel-Reid, S.4    Liu, X.5    Siminovitch, K.6    Messner, H.A.7    Lipton, J.H.8
  • 18
    • 52649177063 scopus 로고    scopus 로고
    • Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
    • Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, Mahon FX: Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood (2008) 112(5):2024-2027.
    • (2008) Blood , vol.112 , Issue.5 , pp. 2024-2027
    • Dulucq, S.1    Bouchet, S.2    Turcq, B.3    Lippert, E.4    Etienne, G.5    Reiffers, J.6    Molimard, M.7    Krajinovic, M.8    Mahon, F.X.9
  • 19
    • 57049129248 scopus 로고    scopus 로고
    • OCT1 (SLC22A1) R 1C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients
    • Zach O, Krieger O, Foedermayr M, Zellhofer B, Lutz D: OCT1 (SLC22A1) R 1C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients. Leuk Lymphoma (2008) 49(11):2222-2223.
    • (2008) Leuk Lymphoma , vol.49 , Issue.11 , pp. 2222-2223
    • Zach, O.1    Krieger, O.2    Foedermayr, M.3    Zellhofer, B.4    Lutz, D.5
  • 20
    • 40849147041 scopus 로고    scopus 로고
    • EGFR antagonists in cancer treatment
    • Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med (2008) 358(11):1160-1174.
    • (2008) N Engl J Med , vol.358 , Issue.11 , pp. 1160-1174
    • Ciardiello, F.1    Tortora, G.2
  • 23
    • 0040886242 scopus 로고    scopus 로고
    • Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1
    • Gebhardt F, Zanker KS, Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem (1999) 274(19): 13176-13180.
    • (1999) J Biol Chem , vol.274 , Issue.19 , pp. 13176-13180
    • Gebhardt, F.1    Zanker, K.S.2    Brandt, B.3
  • 24
    • 61449182121 scopus 로고    scopus 로고
    • Principles of cancer therapy: Oncogene and non-oncogene addiction
    • Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell (2009) 136(5): 823-837.
    • (2009) Cell , vol.136 , Issue.5 , pp. 823-837
    • Luo, J.1    Solimini, N.L.2    Elledge, S.J.3
  • 26
    • 34250828460 scopus 로고    scopus 로고
    • Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response
    • DOI 10.1245/s10434-007-9409-5
    • Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, Arnoletti JP: Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism infuences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol (2007) 14(7):2150-2158. (Pubitemid 46988271) (Pubitemid 46988271)
    • (2007) Annals of Surgical Oncology , vol.14 , Issue.7 , pp. 2150-2158
    • Tzeng, C.-W.D.1    Frolov, A.2    Frolova, N.3    Jhala, N.C.4    Howard, J.H.5    Vickers, S.M.6    Buchsbaum, D.J.7    Heslin, M.J.8    Arnoletti, J.P.9
  • 29
    • 68949208058 scopus 로고    scopus 로고
    • Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with geftinib
    • Ma F, Sun T, Shi Y, Yu D, Tan W, Yang M, Wu C, Chu D, Sun Y, Xu B, Lin D: Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with geftinib. Lung Cancer (2009) 66(1):114-119.
    • (2009) Lung Cancer , vol.66 , Issue.1 , pp. 114-119
    • Ma, F.1    Sun, T.2    Shi, Y.3    Yu, D.4    Tan, W.5    Yang, M.6    Wu, C.7    Chu, D.8    Sun, Y.9    Xu, B.10    Lin, D.11
  • 30
    • 34547841540 scopus 로고    scopus 로고
    • The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib
    • DOI 10.1016/j.ejphar.2007.05.015, PII S0014299907006140
    • Nie Q, Wang Z, Zhang GC, An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL: The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with geftinib. Eur J Pharmacol (2007) 570(1-3):175-181. (Pubitemid 47247671) (Pubitemid 47247671)
    • (2007) European Journal of Pharmacology , vol.570 , Issue.1-3 , pp. 175-181
    • Nie, Q.1    Wang, Z.2    Zhang, G.-c.3    An, S.-j.4    Lin, J.-y.5    Guo, A.-l.6    Li, R.7    Gan, B.8    Huang, Y.9    Mok, T.S.10    Wu, Y.-l.11
  • 31
    • 40949096067 scopus 로고    scopus 로고
    • Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
    • DOI 10.1038/sj.tpj.6500444, PII 6500444
    • Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist R, Lynch TJ, Christiani DC: Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with geftinib. Pharmacogenomics J (2008) 8(2):129-138. (Pubitemid 351411549) (Pubitemid 351411549)
    • (2008) Pharmacogenomics Journal , vol.8 , Issue.2 , pp. 129-138
    • Liu, G.1    Gurubhagavatula, S.2    Zhou, W.3    Wang, Z.4    Yeap, B.Y.5    Asomaning, K.6    Su, L.7    Heist, R.8    Lynch, T.J.9    Christiani, D.C.10
  • 34
    • 33644841038 scopus 로고    scopus 로고
    • Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin effcacy in patients with advanced colorectal cancer
    • Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Tsao-Wei DD, Yun J, Gordon M, Press OA, Rhodes K et al: Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin effcacy in patients with advanced colorectal cancer. Clin Colorectal Cancer (2005) 5(2):124-131.
    • (2005) Clin Colorectal Cancer , vol.5 , Issue.2 , pp. 124-131
    • Zhang, W.1    Stoehlmacher, J.2    Park, D.J.3    Yang, D.4    Borchard, E.5    Gil, J.6    Tsao-Wei, D.D.7    Yun, J.8    Gordon, M.9    Press, O.A.10    Rhodes, K.11
  • 35
    • 11244319884 scopus 로고    scopus 로고
    • A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter
    • Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr, Ratain MJ: A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 65(1):46-53. (Pubitemid 40070794) (Pubitemid 40070794)
    • (2005) Cancer Research , vol.65 , Issue.1 , pp. 46-53
    • Liu, W.1    Innocenti, F.2    Wu, M.H.3    Desai, A.A.4    Dolan, M.E.5    Cook Jr., E.H.6    Ratain, M.J.7
  • 38
    • 36549047976 scopus 로고    scopus 로고
    • Pharmacogenetics of EGFR and VEGF inhibition
    • DOI 10.1016/j.drudis.2007.10.016, PII S1359644607004564
    • Pander J, Gelderblom H, Guchelaar HJ: Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today (2007) 12(23-24):1054-1060. (Pubitemid 350180563) (Pubitemid 350180563)
    • (2007) Drug Discovery Today , vol.12 , Issue.23-24 , pp. 1054-1060
    • Pander, J.1    Gelderblom, H.2    Guchelaar, H.-J.3
  • 40
    • 34548240764 scopus 로고    scopus 로고
    • Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
    • Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD: Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther (2007) 6(3):432-438. (Pubitemid 47328313) (Pubitemid 47328313)
    • (2007) Cancer Biology and Therapy , vol.6 , Issue.3 , pp. 432-438
    • Li, J.1    Cusatis, G.2    Brahmer, J.3    Sparreboom, A.4    Robey, R.W.5    Bates, S.E.6    Hidalgo, M.7    Baker, S.D.8
  • 44
    • 84971580244 scopus 로고
    • Absence of evidence is not evidence of absence
    • Altman DG, Bland JM: Absence of evidence is not evidence of absence. BMJ (1995) 311(7003):485.
    • (1995) BMJ , vol.311 , Issue.7003 , pp. 485
    • Altman, D.G.1    Bland, J.M.2
  • 45
    • 27844492326 scopus 로고    scopus 로고
    • Combinatorial pharmacogenetics
    • DOI 10.1038/nrd1874, PII N1874
    • Wilke RA, Reif DM, Moore JH: Combinatorial pharmacogenetics. Nat Rev Drug Discov (2005) 4(11):911-918. (Pubitemid 41637693) (Pubitemid 41637693)
    • (2005) Nature Reviews Drug Discovery , vol.4 , Issue.11 , pp. 911-918
    • Wilke, R.A.1    Reif, D.M.2    Moore, J.H.3
  • 46
    • 73949120791 scopus 로고    scopus 로고
    • Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate effcacy and tolerability in rheumatoid arthritis
    • Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ, Kremer JM: Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate effcacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics (2009) 19(12):935-944.
    • (2009) Pharmacogenet Genomics , vol.19 , Issue.12 , pp. 935-944
    • Dervieux, T.1    Wessels, J.A.2    Van Der Straaten, T.3    Penrod, N.4    Moore, J.H.5    Guchelaar, H.J.6    Kremer, J.M.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.